Skip to main content
. 2020 Oct 11;12(10):2919. doi: 10.3390/cancers12102919

Figure 7.

Figure 7

RECQL4 depletion does not sensitize LN229 glioma cells to temozolomide or olaparib. Analyses of viability and proliferation of WT and RECQL4-deficient LN229 cells exposed for 72 h to TMZ (250 and 500 µM) (A,B) or olaparib (5 and 10 µM) (D,E). The results were normalized to control cells (CTRL) and represent means ± SEM (n =4). Statistical significance was determined by RM two-way ANOVA, with followed by Tukey’s HSD post hoc test. Representative immunoblots show the levels of cell death, proliferation and cell cycle proteins after the treatments of WT and RECQL4 KO LN229 cells with TMZ (C) or olaparib (F). β-Actin was used as a loading control.